Page 33 - Read Online

Marchand-Adam et al. Rare Dis Orphan Drugs J 2023;2:3 https://dx.doi.org/10.20517/rdodj.2022.24 Page 9 of 11

Financial support and sponsorship
Not applicable.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Lecaille F, Kaleta J, Brömme D. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent
developments in inhibitor design. Chem Rev 2002;102:4459-88. DOI PubMed
2. Turk V, Stoka V, Vasiljeva O, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys
Acta 2012;1824:68-88. DOI PubMed PMC
3. Brix K, Dunkhorst A, Mayer K, Jordans S. Cysteine cathepsins: cellular roadmap to different functions. Biochimie 2008;90:194-207.
DOI PubMed
4. Kramer L, Turk D, Turk B. The future of cysteine cathepsins in disease management. Trends Pharmacol Sci 2017;38:873-98. DOI
PubMed
5. Lecaille F, Brömme D, Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie 2008;90:208-26. DOI
PubMed
6. Brömme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs
2009;18:585-600. DOI PubMed PMC
7. Novinec M, Lenarčič B. Cathepsin K: a unique collagenolytic cysteine peptidase. Biol Chem 2013;394:1163-79. DOI PubMed
8. Qian D, He L, Zhang Q, et al. Cathepsin K: a versatile potential biomarker and therapeutic target for various cancers. Curr Oncol
2022;29:5963-87. DOI PubMed PMC
9. Rocho FR, Bonatto V, Lameiro RF, Lameira J, Leitão A, Montanari CA. A patent review on cathepsin K inhibitors to treat
osteoporosis (2011-2021). Expert Opin Ther Pat 2022;32:561-73. DOI PubMed
10. Verbovšek U, Van Noorden CJ, Lah TT. Complexity of cancer protease biology: cathepsin K expression and function in cancer
progression. Semin Cancer Biol 2015;35:71-84. DOI PubMed
11. Troen BR. The regulation of cathepsin K gene expression. Ann NY Acad Sci 2006;1068:165-172. DOI PubMed
12. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;27:157-62. DOI
PubMed
13. Jaffer FA, Kim DE, Quinti L, et al. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable
fluorescence sensor. Circulation 2007;115:2292-8. DOI PubMed
14. Lecaille F, Weidauer E, Juliano MA, Brömme D, Lalmanach G. Probing cathepsin K activity with a selective substrate spanning its
active site. Biochem J 2003;375:307-12. DOI PubMed PMC
15. Lemke C, Benýšek J, Brajtenbach D, et al. An activity-based probe for cathepsin K imaging with excellent potency and selectivity. J
Med Chem 2021;64:13793-806. DOI PubMed
16. Richard ET, Morinaga K, Zheng Y, et al. Design and synthesis of cathepsin-k-activated osteoadsorptive fluorogenic sentinel (OFS)
probes for detecting early osteoclastic bone resorption in a multiple myeloma mouse model. Bioconjug Chem 2021;32:916-27. DOI
PubMed PMC
17. Li Z, Hou WS, Brömme D. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates.
Biochemistry 2000;39:529-36. DOI PubMed
18. Li Z, Hou W-S, Escalante-Torres CR, et al. Collagenase activity of cathepsin K depends on complex formation with chondroitin
sulfate. J Biol Chem 2002;277:28669-28676. DOI PubMed
19. Fonović M, Turk B. Cysteine cathepsins and extracellular matrix degradation. Biochim Biophys Acta 2014;1840:2560-70. DOI
PubMed
20. Brisson L, Reshkin SJ, Goré J, Roger S. pH regulators in invadosomal functioning: proton delivery for matrix tasting. Eur J Cell Biol
2012;91:847-60. DOI PubMed
21. Punturieri A, Filippov S, Allen E, et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient